Tenderwize
Zurück zur Suche

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 250 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)hydroxid-Polymaltose-Komplex, ATC B03AC01

50/100

Opportunity Score

PromisingLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Supply of pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) to AOK Bayern insured persons
  • Conclusion of non-exclusive discount agreements (rabattverträge) under §130a(8) SGB V
Vollständige Zusammenfassung anzeigen

The AOK Bayern (Bavaria Health Insurance) is conducting an open-house model for non-exclusive discount agreements on pharmaceutical products containing iron(III)hydroxide-polymaltose complex (ATC B03AC01) under §130a(8) SGB V. This is not a typical procurement procedure; any interested pharmaceutical company meeting eligibility criteria can sign identical, non-negotiable agreements. Contracts have a fixed end date of 30 June 2027, with possible start from 1 July 2025. The open-house is open until 5 May 2027. No estimated contract value is provided. The process is governed by German social law, not procurement law. Submission can be in paper form (hand-signed) or electronically with a qualified electronic signature. Only pharmaceutical companies can participate.

Risiken

No guaranteed purchase volume or minimum order quantity; revenue depends on actual prescriptions and market share.

Open-house agreements may be overridden by future formal framework contracts (bundesweit oder landesspezifisch) for the...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only pharmaceutical companies (pharmazeutische Unternehmen) can participate

Administrative

  • Submission of signed contract, completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Hand-signed paper documents in duplicate OR electronically with qualified electronic signature via the communication area of the dtvp portal

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria; participation is open to all qualified pharmaceutical companies.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house discount agreements for iron(III)hydroxide-polymaltose complex, ATC B03AC01

Non-exclusive discount agreements for the active ingredient iron(III)hydroxide-polymaltose complex (ATC B03AC01). Contracts are identical for all participants, no individual negotiation. Performance location: Bavaria, Germany. Contract period: 1 July 2025 to 30 June 2027. Early termination possible with one month notice. Agreements automatically superseded if a nationwide or state-specific framework discount contract for the same active ingredient is concluded via a formal procedure.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jun 2025 - Jun 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; participation is open to all qualified pharmaceutical companies.

Frist

Deadline May 05, 2027

Vergabedetails

Veröffentlichungsdatum
15 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
315689-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30